PURPOSE: To perform an external validation of the EORTC risk tables and to evaluate their applicability in the patients of our institution by comparing the actual risk of recurrence and progression in our series to those obtained through the application of the EORTC tables. METHODS: Retrospective study, based on a prospective cohort of 417 patients in follow-up with primary TaT1 bladder tumors, operated on in our center between 1998 and 2008 and collected in our database. Risk scores were assigned depending on the tumor characteristics to divide our series into four risk groups according to these ratings. An analysis of survival was carried out to calculate the probability of recurrence by the method of Kaplan-Meier. RESULTS: A total of 417 patients with a median follow-up of 59 months were studied. The overall recurrence and progression rates of our series were 25.95% (21.97-30.49) and 4.86% (3.16-7.43) at 1 year and 53.46% (48.06-59.05) and 8.43% (5.95-11.86) at 5 years, respectively. When we compare our rates of recurrence and progression by groups with the corresponding values from Sylvester's publication, an overlapping of the confidence intervals between both populations is detected. CONCLUSIONS: In terms of the applicability of the EORTC risk tables in our patients' population, we conclude that these tables predict accurately the clinical course of patients with NMIBC. Due to the sample size of our study, we can only validate the recurrence model of the EORTC tables.
PURPOSE: To perform an external validation of the EORTC risk tables and to evaluate their applicability in the patients of our institution by comparing the actual risk of recurrence and progression in our series to those obtained through the application of the EORTC tables. METHODS: Retrospective study, based on a prospective cohort of 417 patients in follow-up with primary TaT1bladder tumors, operated on in our center between 1998 and 2008 and collected in our database. Risk scores were assigned depending on the tumor characteristics to divide our series into four risk groups according to these ratings. An analysis of survival was carried out to calculate the probability of recurrence by the method of Kaplan-Meier. RESULTS: A total of 417 patients with a median follow-up of 59 months were studied. The overall recurrence and progression rates of our series were 25.95% (21.97-30.49) and 4.86% (3.16-7.43) at 1 year and 53.46% (48.06-59.05) and 8.43% (5.95-11.86) at 5 years, respectively. When we compare our rates of recurrence and progression by groups with the corresponding values from Sylvester's publication, an overlapping of the confidence intervals between both populations is detected. CONCLUSIONS: In terms of the applicability of the EORTC risk tables in our patients' population, we conclude that these tables predict accurately the clinical course of patients with NMIBC. Due to the sample size of our study, we can only validate the recurrence model of the EORTC tables.
Authors: K Kurth; U Tunn; R Ay; F H Schröder; M Pavone-Macaluso; F Debruyne; F ten Kate; M de Pauw; R Sylvester Journal: J Urol Date: 1997-08 Impact factor: 7.450
Authors: Richard J Sylvester; Adrian P M van der Meijden; Willem Oosterlinck; J Alfred Witjes; Christian Bouffioux; Louis Denis; Donald W W Newling; Karlheinz Kurth Journal: Eur Urol Date: 2006-01-17 Impact factor: 20.096
Authors: Jesus Fernandez-Gomez; Rosario Madero; Eduardo Solsona; Miguel Unda; Luis Martinez-Piñeiro; Marcelino Gonzalez; Jose Portillo; Antonio Ojea; Carlos Pertusa; Jesus Rodriguez-Molina; Jose Emilio Camacho; Mariano Rabadan; Ander Astobieta; Manuel Montesinos; Santiago Isorna; Pedro Muntañola; Anabel Gimeno; Miguel Blas; Jose Antonio Martinez-Piñeiro Journal: J Urol Date: 2009-09-16 Impact factor: 7.450
Authors: V Hernández; M Alvarez; E de la Peña; N Amaruch; M D Martín; J M de la Morena; V Gómez; C Llorente Journal: Urology Date: 2009-04-18 Impact factor: 2.649
Authors: D W Newling; M R Robinson; P H Smith; D Byar; R Lockwood; I Stevens; M De Pauw; R Sylvester Journal: Eur Urol Date: 1995 Impact factor: 20.096
Authors: Ines A Ederer; Ilaria Lucca; Sebastian L Hofbauer; Michael Haidinger; Andrea Haitel; Martin Susani; Shahrokh F Shariat; Tobias Klatte Journal: World J Urol Date: 2015-04-10 Impact factor: 4.226
Authors: Se Young Choi; Jae Hyung Ryu; In Ho Chang; Tae-Hyoung Kim; Soon Chul Myung; Young Tae Moon; Kyung Do Kim; Jin Wook Kim Journal: Korean J Urol Date: 2014-10-10
Authors: Moniek M Vedder; Mirari Márquez; Esther W de Bekker-Grob; Malu L Calle; Lars Dyrskjøt; Manoils Kogevinas; Ulrika Segersten; Per-Uno Malmström; Ferran Algaba; Willemien Beukers; Torben F Ørntoft; Ellen Zwarthoff; Francisco X Real; Nuria Malats; Ewout W Steyerberg Journal: PLoS One Date: 2014-06-06 Impact factor: 3.240
Authors: E Xylinas; M Kent; L Kluth; A Pycha; E Comploj; R S Svatek; Y Lotan; Q-D Trinh; P I Karakiewicz; S Holmang; D S Scherr; M Zerbib; A J Vickers; S F Shariat Journal: Br J Cancer Date: 2013-08-27 Impact factor: 7.640
Authors: E López de Maturana; A Picornell; A Masson-Lecomte; M Kogevinas; M Márquez; A Carrato; A Tardón; J Lloreta; M García-Closas; D Silverman; N Rothman; S Chanock; F X Real; M E Goddard; N Malats Journal: BMC Cancer Date: 2016-06-03 Impact factor: 4.430